Skip to main content

Portfolio

We have a broad portfolio covering a wide range of therapeutic areas, and across modalities, from small molecules to cell therapy. Many have already attracted investments from top-tier investors such as Pureos Bioventures, NEA, Orbimed, Syncona, Sofinnova, the Novartis Venture Fund, Biomedinvest, Boehringer Ingelheim Venture Fund, Kurma Partners, Sunstone Life Science Ventures, Ysios Capital, Morningside Venture Investments, Jeito Capital, Versant Ventures, Novo Holdings, RA Capital Management and others.

Financed: $50M raised 

Combining cell-shielding and immunotherapies to safely treat hematologic disorders, targeting diseased cells while preserving healthy ones and resisting immunotherapy depletion

Financed: $366M raised

Anti-Claudin-1 antibody-drug conjugates and monoclonal antibodies to treat cancer and reverse fibrosis

Financed: $155M raised

Cytokine based cancer therapies harnessing the power of the immune system

Financed: $35M raised

mRNA platform for local regenerative medicine-based therapeutics

Incubating

A novel class of oral immunosuppressive therapies for chronic T cell-mediated autoimmune diseases

Financed: $39M raised

Developing small molecule inhibitors addressing non mutational mechanisms of cancer therapy evasion

Acquired by Repertoire Immune Medicines

Functional ID of (neo)antigens for cancer, immunological and infectious diseases.

Financed: $42M raised
Acquired by BI for $507M

Intracellular delivery of therapeutic payloads using bacteria, exploiting bacterial tumor targeting

Seed

Bacterial mixes as microbiome therapeutics in IBD and oncology based on mixed-culture technology

Incubating

Cyclic short peptides platform for the selective capturing of metal ions in metal-related pathologies

Financed: $41.5M raised
Stopped

Glycomimetic platform for removing auto-antibodies in autoimmune neuropathies

Financed

Developing gene logic circuits to accurately identify complex disease patterns and enable in-vivo cancer cell targeting and treatment

Incubating

Native proteins-derived biologics platform to produce high-affinity and low-immunogenicity therapeutics for autoimmune diseases

Stopped

First-in-class therapeutics to stop neurodegenerative diseases with a selective small molecule approach

Incubating

Leveraging an AI-driven discovery platform for highly specific inhibition of mTOR and hard to drug targets

Financed: $16M raised

Highly potent, targeted soluble T cell receptor therapies for solid tumors, using AI-guided engineering to enhance affinity, stability, and safety

Seed / Incubating

Platform to create compartment locked biologics for higher local retention and fast systemic degradation

Seed / Incubating

Antibody-based discovery platform against novel druggable secreted growth factors reprogramming diseased cells towards uncontrolled growth

Incubating

Novel approach to safely restore microtubule function for cardiovascular and neurodegenerative diseases

Financed

Breaking efficacy ceilings in inflammatory and autoimmune diseases

Incubating

RNA-based therapeutics targeting mitochondrial function and ER stress for liver disease treatment

Stopped

Developing novel inflammasome inhibitors

Financed: $25M raised

First-in-class endocannabinoid modulators to restore brain function in CNS disorders, targeting stress, anxiety, and related conditions

Incubating

Targeting endometriosis and other chronic fibro-inflammatory disease with immunotherapy solutions

Incubating

Antibodies against novel stromal cell targets acting locally on the immune system to treat chronic immune-mediated diseases

Incubating

Modulating muscle secretome-derived novel targets for the treatment of metabolic diseases

Application cycle is now open!

The next deadline is 8 May 2025